Disaggro (Zalunfiban) for Pre-hospital Treatment of STEMI: Phase 3 Results to Be Presented at AHA 2025
CeleCor Therapeutics reposted from Dirk Sibbing on LinkedIn:
”Excited to see the news about our Phase 3 CeleBrate trial of Disaggro™ (zalunfiban) being picked up – appreciate the share Dirk Sibbing.
The full study results will be presented as part of the Late-Breaking Science Sessions at the American Heart Association Scientific Sessions (AHA 2025) in New Orleans on November 10, 2025.
Stay tuned!”
”A new drug on the horizon for pre-hospital treatment of STEMI patients
Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action
Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics
This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…
Still we are loosing too many patients pre-hospital and before we see them in the cath lab…
Results will be presented as LBCT at AHA 2025 in New Orleans”
Read the full article here.
Stay updated on the emerging with Hemostasis Today.
-
Oct 13, 2025, 02:47Thomas Reiser: Don't Miss This ISTH Research Recap with Robert Sidonio, Cedric Hermans and Michael Makris
-
Oct 12, 2025, 01:30Elvira Grandone: Pregnancy and VTE - Still A Relevant Cause of Maternal Mortality
-
Oct 12, 2025, 01:29Emilia Arturo: Consider Submitting the Paper and Its Reviews for a Second Look Rapid Response From One of These Blood Journals
-
Oct 12, 2025, 01:22Christina (Tina) P.: APS is Responsible for 1 in 3 Strokes in People Under 50 and The N1 Cause of Stroke in Young People
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 01:32Camila V. Blair and Colleagues on The Association of CAD by Coronary CT Angiography and Cardiovascular Outcomes in Psoriatic Disease
-
Oct 12, 2025, 01:26Caroline Dixon and Colleagues on LMWH Dosing to Reduce The Risk of VTE in Pregnant Women With Inherited ATD
-
Oct 12, 2025, 01:26Nagesh Ramesh: 80% of The World’s Population Lives in LMICs But They Collect Less Than 10% of The World’s Plasma
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 13, 2025, 03:15Arun V. J: They Chose Death Over A Blood Transfusion — And Here’s Why I Stopped Judging Them
-
Oct 13, 2025, 03:13Rahaf Ajaj: The Persistent Gender Gap in Nobel Prizes - A Call for Greater Inclusion
-
Oct 13, 2025, 02:50Emmanuel J Favaloro: Again Promoting World Thrombosis Day - October 13
-
Oct 12, 2025, 01:33Stefan Galisch: This Week We Celebrate IPAW– A Global Initiative That Raises Awareness of The Life-saving Importance of Plasma Donation
-
Oct 12, 2025, 01:31Fabio Eisfeld: Plasma-derived Drugs Cannot Be Produced Synthetically, They Depend Entirely On The Generosity of Healthy Donors